Unlock stock picks and a broker-level newsfeed that powers Wall Street.
CLASS ACTION UPDATE for UMC, ZGNX and BSX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

In This Article:

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

United Microelectronics Corporation (UMC)

Class Period: October 28, 2015 - November 1, 2018
Lead Plaintiff Deadline : May 13, 2019
Join the action: https://www.zlk.com/pslra-1/united-microelectronics-corporation-loss-form?prid=1442&wire=1

Allegations: United Microelectronics Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) UMC conspired with Fujian to steal trade secrets from Micron relating to its research and development of Dynamic Random-Access Memory ("DRAM"); (ii) UMC hired former Micron employees for the purpose of stealing such information from Micron; (iii) the foregoing conduct placed UMC and certain of its employees at an increased risk of criminal and regulatory investigation by the U.S. government; and (iv) as a result, UMC’s public statements were materially false and misleading at all relevant times.

To learn more about the United Microelectronics Corporation class action contact jlevi@levikorsinsky.com.

Zogenix, Inc. (ZGNX)

Class Period: February 6, 2019 - April 8, 2019
Lead Plaintiff Deadline : June 11, 2019
Join the action: https://www.zlk.com/pslra-1/zogenix-inc-loss-form?prid=1442&wire=1

Allegations: Zogenix, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Zogenix, Inc. class action contact jlevi@levikorsinsky.com.

Boston Scientific Corporation (BSX)

Class Period: February 26, 2015 - April 16, 2019
Lead Plaintiff Deadline : June 24, 2019
Join the action: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-form?prid=1442&wire=1

Allegations: Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific’s surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific’s continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.